Results 171 to 180 of about 26,349 (219)

First-in-class cardiac myosin inhibitor reduces symptoms of HCM

Nature Reviews Cardiology, 2020
Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
Gregory Lim
exaly   +3 more sources

FDA approves first cardiac myosin inhibitor

Nature Reviews Drug Discovery, 2022
Mullard Asher
exaly   +2 more sources

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

International Journal of Toxicology
Aficamten (CK-3773274) is a cardiac myosin inhibitor in development for the treatment of hypertrophic cardiomyopathy (HCM), a commonly inherited heart condition often characterized as a disease of the sarcomere. Aficamten reduces pathologic cardiac hypercontractility by selectively binding to an allosteric site on cardiac myosin.
Fady Malik, Eva R Chin, Michael Pugsley   +2 more
exaly   +3 more sources

Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management

Annals of Pharmacotherapy, 2023
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to
Alyssa Sykuta, Connie H. Yoon, Sarah Baldwin, Natalie I. Rine, Michael Young, Adam Smith   +5 more
openaire   +2 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Srihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

Annals of Pharmacotherapy, 2022
Objective: To assess mavacamten’s role in hypertrophic cardiomyopathy treatment. Data Sources: In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to ...
Joseph D. Dalo, Nissen D. Weisman, C. Michael White   +2 more
openaire   +2 more sources